Cellectar opens manufacturing facility for radiolabeled CLR1404
MADISON, Wisconsin-Cellectar has opened its new $3.3 million radiopharmaceutical research, development, and manufacturing facility and headquarters in Madison. The facility allows Cellectar to manufacture and radiolabel its lead compound CLR1404, a phospholipid ether combined with 131Iodine, in compliance with Good Manufacturing Practices.
MammoScreen AI Tool Improves Diagnostic Performance of Radiologists in Detecting Breast Cancer
December 16th 2020This study demonstrated that the concurrent use of this new artificial intelligence tool alongside mammography improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
Preliminary Results Suggest AB-MR Detects Breast Cancers that 3-D Mammograms May Miss
November 29th 2020This study found that abbreviated breast magnetic resonance imaging as a supplemental screening test in women with dense breasts shows an increase in cancer detection over digital breast tomosynthesis screening.
DeepSurv Displays Possible Benefits in Prognostic Evaluation, Treatment Recommendation
July 20th 2020The deep learning survival neural network model demonstrated the potential to provide personalized treatment recommendations based on real clinical data in patients with non-small cell lung cancer.